NKTR Nektar Therapeutics

18.1
-0.09  -0%
Previous Close 18.19
Open 18.25
Price To Book 2.04
Market Cap 3,172,467,599
Shares 175,274,453
Volume 3,000,549
Short Ratio
Av. Daily Volume 2,244,227

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 updated melanoma data June 1, 2019 noted ORR was 53% (34% CR);.
NKTR-214 + OPDIVO (nivolumab) - PIVOT-2
Urothelial carcinoma, Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers
Phase 1/2 commencement of dosing announced September 12, 2017. Initial data presented at ASCO 2018
NKTR-214 + TECENTRIQ + KEYTRUDA (PROPEL)
Solid tumors - cancer
Phase 3 second trial did not meet endpoint - April 5, 2017.
Cipro DPI
Bronchiectasis
PDUFA date August 29, 2019. Company noted the date might not be met due to the postponement of an advisory committee meeting.
NKTR-181
Lower back pain
Phase 3 data released November 24, 2017. Endpoints not met.
Inhaled Amikacin Solution (BAY41-6551T)
Gram-Negative Pneumonia (INHALE 1)
Phase 3 topline data mid March 2015 did not reach primary endpoint.
Etirinotecan pegol NKTR-102 (BEACON)
Cancer - Metastatic Breast Cancer
Approved November 16, 2015.
ADYNOVATE
Hemophilia A
Approved September 16, 2014.
MOVANTIK (Naloxegol)
Opioid-induced constipation (OIC)
Phase 1/2 initial data March 1, 2019 noted ORR 2/11 ( 18%) - maximum tolerated dose has not been reached.
NKTR-262 and NKTR-214 - REVEAL
Solid tumors
Phase 1b data presented at EULAR June 13, 2019 - safe and well-tolerated.
NKTR-358
Systemic lupus erythematosus (SLE)
Phase 2 data presented at ASCO June 3, 2019.
NKTR-214 and nivolumab
Sarcomas

Latest News

  1. Bragar Eagel & Squire, P.C. is Investigating Nektar Therapeutics, Inc. (NASDAQ: NKTR) on Behalf of Stockholders and Encourages Nektar Investors to Contact the Firm
  2. Edited Transcript of NKTR earnings conference call or presentation 8-Aug-19 9:00pm GMT
  3. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Nektar Therapeutics (NKTR)
  4. INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  5. Nektar Erases $1.8 Billion of Value on Doubts Over Its Cancer Drug
  6. Why Nektar Therapeutics Stock Is Falling Again Today
  7. Nektar Therapeutics Drops Sharply for Second Day After Admitting Batch Issues
  8. 3 Big Stock Charts for Monday: Xilinx, News Corp and Gilead Sciences
  9. INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  10. Glancy Prongay & Murray LLP Announces Investigation on Behalf of Nektar Therapeutics Investors
  11. Why Farfetch, Waitr Holdings, and Nektar Therapeutics Slumped Today
  12. Biotech Crashes 29% After Bad Drug Likely Skewed Cancer Tests
  13. INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Nektar Therapeutics Investors
  14. Pharma companies Amarin, Nektar Therapeutics nosedive on product concerns
  15. Large Option Trader Buying Nektar Calls Following Stock Crash
  16. Drugmakers Put Bad Spin on a Bizarre Week
  17. Why Nektar Therapeutics Stock Is Crashing Today
  18. Investor Alert: Ademi & O'Reilly, LLP Investigates Possible Securities Fraud of Nektar Therapeutics
  19. Biotech Investors Jolted Out of Summer Lull as High-Fliers Sink